Highlights:
-TRILOGY-ACS shows no advantage for prasugrel over clopidogrel
-Renal denervation may be cost-effective for resistant hypertension
-German registry shows TAVI restricted to high-risk patients and with in-hospital mortality comparable to surgery
-Profile: David Holmes
[pdfviewer width=”100%” height=”940px” beta=”true”]http://cardiovascularnews.com/wp-content/uploads/sites/14/2016/06/27-Cardiovascular-News_low-res_EU.pdf[/pdfviewer]
